Area of research
Cancer Research · Oncology
Research interest
Research interests include Capecitabine, Medicine, Docetaxel, Epirubicin, Internal medicine, and Triple-negative breast cancer.
Exportin-T Promotes Breast Cancer Progression via PI3K/AKT/mTOR Signaling Pathway
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker Analysis
Exploration of Specific Population for Adjuvant Capecitabine Escalation Therapy in Early-Stage Triple-Negative Breast Cancer: A Retrospective Biological Sample Analysis of the CBCSG010 Clinical Trial
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Abstract GS1-08: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial
Cbcsg-10: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer.